Patents by Inventor Elizabeth Jane Franzmann

Elizabeth Jane Franzmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for the Treatment of Head and Neck Squamous Cell Carcinoma
    Publication number: 20150374848
    Abstract: This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 31, 2015
    Inventors: Luis A.G. da Cruz, Elizabeth Jane Franzmann
  • Methods for the Treatment of Head and Neck Squamous Cell Carcinoma
    Publication number: 20130224108
    Abstract: This invention relates to the staging, diagnosis, and treatment of cancerous diseases, particularly to the use of monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human head and neck squamous cell carcinomas. The invention further relates to binding assays, which utilize the monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. In particular aspects, the CDMAB used in the methods of the invention is an anti-CD44 antibody, which may be the antibody produced by the hybridoma deposited with the ATCC having accession number PTA-4621 and/or a chimeric or humanized version thereof.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 29, 2013
    Applicants: UNIVERSITY OF MIAMI, HOFFMANN-LA ROCHE INC.
    Inventors: Luis A.G. Da Cruz, Elizabeth Jane Franzmann